A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection

详细信息    查看全文

• 作者：Xuetao Guo^a ; ¹ ; Lixia Qiu^c ; ¹ ; Yue Wang^e ; ¹ ; Yonghong Wang^d ; ¹ ; Qian Wang^b ; Lei Song^e ; Yali Li^e ; Ke Huang^e ; Xinxin Du^e ; Wensheng Fan^e ; Shufang Jiang^e ; Qianqing Wang^f ; Haoyang Li^b ; Yi Yang^g ; Yuanguang Meng^e ; ² ; Yun Zhu^h ; ² ; Lu Lu^b ; ² ; Shibo Jiang^b ; ⁱ ; ² ; ^{shibojiang@fudan.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cervical cancer ; Human papilloma virus (HPV) ; Antiviral therapy ; Clinical trial
• 刊名：Microbes and Infection
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：18
• 期：2
• 页码：148-152
• 全文大小：184 K

文摘

Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV biological dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical biological agent for the treatment of cervical HPV infection.